Clinical trials: Cerebrospinal Fluid
- Condition Cerebrospinal Fluid
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers
The objective of this study is to determine the effects of cerebrospinal fluid sampling rate on biomarker levels of young, healthy volunteers.
- Trial name
- NCT01126567
- Testing
- Sampling Rate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Abbott
Alzheimer's Disease
A Study to Evaluate the Use of an Indwelling Catheter to Obtain Cerebrospinal Fluid (CSF) by Low-rate Continuous Sampling (MK-0000-211)
This is a study to evaluate the feasibility and tolerability of low-rate continuous Cerebrospinal Fluid (CSF) sampling and to estimate the number of participants who exhibit severe baseline instability of CSF amyloid beta isoform…
- Trial name
- NCT01325662
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma
The primary purpose of this study is to investigate the effects of JNJ-54175446 (dose response) on levels of Aβ fragments (Aβ1-42, Aβ1-40, Aβ1-38, Aβ1-37) in plasma and cerebrospinal fluid (CSF), the effects of JNJ-54175446 on…
- Trial name
- NCT02933762
- Testing
- JNJ-54175446
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)
This is a First in human (FIH) single ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PKs) of BIIB118 following single oral doses in healthy human subjects
- Trial name
- NCT02443740
- Testing
- BIIB118
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Biogen
West Nile Virus
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier.
- Trial name
- NCT00387283
- Testing
- AVI-4020 Injection
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Safety, Peripheral Neuropathy
Xanamem™ in Healthy Elderly Subjects
Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body.
- Conditions
- Safety, Peripheral Neuropathy, Cortisol, Central Nervous System
- Trial name
- XanaHES (NCT03830762)
- Testing
- Xanamem
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Actinogen Medical
Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
The purpose of this study is to evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of multiple doses of ASP3652 in healthy young Caucasian male subjects.
- Conditions
- Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652, Healthy Subjects
- Trial name
- NCT02034734
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects
A clinical trial to investigate the safety and tolerability of single and multiple intranasal (through the nose) dosing with the study drug CHF6467 in 68 healthy adult subjects.
- Trial name
- NCT07163182
- Testing
- CHF6467 Part 1 (SAD), CHF6467 Part 2 (MAD)
- Where
- Bulgaria
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy Adult
Cerebrospinal Fluid Kinetics of Urolithin A
The purpose of this study is to determine the impact of Mitopure® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).
- Trial name
- neURO (NCT07517913)
- Testing
- Mitopure
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amazentis SA
Healthy
Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
Due to the exploratory nature of this trial, there is no primary objective in a confirmatory sense. The study aims to evaluate the effect of different doses of BI 409306 on biomarker and to assess the exposure of BI 409306
- Trial name
- NCT01493570
- Testing
- BI 409306
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer…
- Trial name
- NCT00479219
- Testing
- GSI-953
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Volunteer
A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the pharmacodynamics and pharmacokinetics of RO5508887 in healthy volunteers.
- Trial name
- NCT01592331
- Testing
- RO5508887
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy
A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid
The objectives of this study are to assess the cerebral spinal fluid (CSF) pharmacokinetics and the plasma/CSF pharmacokinetic/pharmacodynamic relationship of ABT-384 in healthy male volunteers.
- Trial name
- NCT01009216
- Testing
- ABT-384
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Abbott
Healthy Adults
Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants
This is a safety, tolerability, and pharmacokinetic study in 2 cohorts of healthy male participants with an option for an additional cohort.
- Trial name
- NCT04994743
- Testing
- CORT113176
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy Subjects
A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)
This is phase 1 investigator-and-subject blind, sponsor open, randomized, placebo controlled, parallel study in healthy subjects to evaluate the pharmacodynamics effect of single oral doses of PF-06648671 on CSF Aβ concentrations…
- Trial name
- NCT02407353
- Testing
- PF-06648671
- Where
- 2 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers
The objectives of this study are to determine the cerebrospinal fluid (CSF) levels of ABT-126 and to examine the effects of ABT-126 on exploratory biomarkers after administration of a single does of ABT-126 in healthy volunteers.
- Trial name
- NCT00912431
- Testing
- ABT-126
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Abbott
Healthy
A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults
This study is designed to observe the safety and concentrations of PF-05297909 and proteins in both blood and cerebrospinal fluid after a single dose of PF-05297909 in healthy adults.
- Trial name
- NCT01462851
- Testing
- PF-05297909 25 mg, PF-05297909 100 mg, PF-05297909 250 mg
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neoplasms
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
Because AVI-4020 Injection was found to cross the blood-brain barrier, and because AVI-4126 (RESTEN-NG) has potential medical benefit to people with a variety of diseases, including cancers, this study is being performed to find…
- Trial name
- NCT00343148
- Testing
- AVI-4126 Injection (RESTEN-NG®)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.